21 August 2024
PureTech
Health plc
Notice of
Half-Yearly Results
PureTech Health
plc (Nasdaq: PRTC, LSE: PRTC)
("PureTech" or the "Company") plans to announce its half-yearly
results for the six months ended June 30, 2024,
on Wednesday, August 28, 2024.
A presentation and conference call
for analysts and shareholders will take place at 9:00am
EDT / 2:00pm BST on the day of publication, and a
webcast of the presentation will be available on the Company's
website at https://investors.puretechhealth.com/events-presentations.
About PureTech
Health
PureTech is a clinical-stage biotherapeutics company
dedicated to giving life to new classes of medicine to change the
lives of patients with devastating diseases. The Company has
created a broad and deep pipeline through its experienced research
and development team and its extensive network of scientists,
clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D
engine has resulted in the development of 29 therapeutics and
therapeutic candidates, including two that have received both U.S.
FDA clearance and European marketing authorization and a third
(KarXT) that has been filed for FDA approval. A number of these
programs are being advanced by PureTech or its Founded Entities in
various indications and stages of clinical development, including
registration enabling studies. All of the underlying programs and
platforms that resulted in this pipeline of therapeutic candidates
were initially identified or discovered and then advanced by the
PureTech team through key validation points.
For more information, visit www.puretechhealth.com or
connect with us on X (formerly Twitter) @puretechh.
Cautionary Note
Regarding Forward-Looking Statements
This press release contains statements that are or
may be forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation those related to PureTech's development plans
and our future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks, uncertainties and other
important factors that could cause actual results, performance and
achievements to differ materially from current expectations,
including, but not limited to, those risks, uncertainties and other
important factors described under the caption "Risk Factors" in our
Annual Report on Form 20-F for the year ended December 31, 2023,
filed with the SEC and in our other regulatory filings. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the Company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements, we
disclaim any obligation to update or revise these forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
UK/EU
Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
puretech@fticonsulting.com
US Media
Nichole Bobbyn
+1 774 278 8273
nichole@tenbridgecommunications.com
